Amicus Therapeutics Inc. Stock
Price
Target price
€9.50
€9.50
-3.550%
-0.35
-3.550%
€18.24
25.04.24 / Tradegate
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amicus Therapeutics Inc. Stock
Heavy losses for Amicus Therapeutics Inc. today as the stock fell by -€0.350 (-3.550%).
Currently there is a rather positive sentiment for Amicus Therapeutics Inc. with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 18 € shows a very positive potential of 89.47% compared to the current price of 9.5 € for Amicus Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Amicus Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | -3.550% | -4.040% | -11.215% | -12.844% | -28.571% | 14.458% | - |
| Opko Health Inc. | -0.050% | -0.982% | 23.925% | -16.662% | -19.340% | -68.292% | -43.684% |
| Catalent Inc. | -0.210% | -0.744% | 0.038% | 34.767% | 26.262% | -45.242% | 51.485% |
| Repligen Corp. | -1.120% | 4.675% | -9.437% | 13.270% | -7.816% | -14.357% | - |
Comments
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $19.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
